Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

shares

(basic and

diluted) 40,181,777 36,317,687 41,120,748 36,368,270

-------------------------------------------------------------

-------------------------------------------------------------

Oncolytics Biotech Inc.

STATEMENTS OF CASH FLOWS

(unaudited)

Cumulative

from

Nine Month Nine Month Three Month Three Month inception

Period Period Period Period on April 2,

Ending Ending Ending Ending 1998 to

September September September September September

30, 2007 30, 2006 30, 2007 30, 2006 30, 2007

$ $ $ $ $

-------------------------------------------------------------------------

OPERATING

ACTIVITIES

Net loss

for the

period (11,556,714) (9,407,419) (3,763,901) (3,425,169) (76,436,780)

Add/(deduct)

non-cash

items

Amortization

- intell-

ectual

property 713,887 647,893 244,299 220,774 4,750,721

Amortization

- property

and

equipment 30,061 43,379 10,197 12,685 437,744

Stock-based

compen-

sation 142,878 293,880 38,909 34,671 4,308,527

Other

non-cash

items - - - - 1,383,537

Net changes

in non-cash

working

capital (179,975) (34,485) 239,121 261,875 1,724,946

-------------------------------------------------------------------------


'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...ies, Inc. today,announced that it has entered into...speed chemistry technologies and capabilities to Z...based biopharmaceutical company which,develops obe...ipose tissue., Under the agreement, Anthill will ...d purification capabilities to assist Zafgen in th...
...inical Picture, Improves,Patient-Physician Communi...a A patients who,use Helixate(R) FS, Antihemophili...ers are now tracking treatment progress in real ti...-art wireless Internet-based,data management syste...llows for a comprehensive view of a patient,s prog...
...ternational Corporation (Nasdaq: PRXL ), a leadin...reveal that U.S. marketing,applications for new mo...,While NME approvals reached a many-year low of 16...) launches declined 19 percent to 25, during 2007,... 2007, up from 21 filed,in 2006, according to PARE...
Other Biology Technology:CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients 2CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients 3CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients 4PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back 2PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back 3PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back 4
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
(Date:12/3/2009)The UK leads the world when it comes to investment in energy efficient technologies research, but Engineering and Physical Sciences Research Council (EPSRC) Chief Executive Dave Delpy believes that mo
(Date:12/2/2009)PHILADELPHIA Children exposed to secondhand cigarette smoke have an increased risk of developing lung cancer in adulthood, even if they never smoked. , Results of this study are published in Cance
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Cornflakes White Bread Could Boost Heart Risk 48653 1Cornflakes White Bread Could Boost Heart Risk 48653 2Cornflakes White Bread Could Boost Heart Risk 48653 3Pennsylvania Patient Safety Authority Hires Patient Safety Liaison 28PSL 29 to Help Healthcare Facilities Implement Guidance 48651 1Pennsylvania Patient Safety Authority Hires Patient Safety Liaison 28PSL 29 to Help Healthcare Facilities Implement Guidance 48651 2Pennsylvania Patient Safety Authority Hires Patient Safety Liaison 28PSL 29 to Help Healthcare Facilities Implement Guidance 48651 3Study shows promise for new cancer stopping therapy 48649 1Study shows promise for new cancer stopping therapy 48649 2
...mans is often associated with decline and a loss o...alled senescence -- is proving to be one of ironic...tory (CSHL) today reported that a particular class...of events in living mice that can limit fibrosis, ... The surprising finding follows on the heels of e...
... . , Bremerhaven, August 19th 2008. German rese...ener Institute for Polar and Marine Research in th...ssage for the first time. Polarstern left the port...and on a southern course and is located right in t...Siberian Sea where geoscientific measurements at t...
...awaii, the Wildlife Conservation Society, Smithso...Fisheries Service and Projecto Meros do Brazil dis...s more than six feet in length and can weigh nearl...be found roaming the tropical reefs of the Eastern...ong the corals and sea grass to evade marine biolo...
Other Biology News:Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage 2Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage 3Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage 4RV Polarstern on its way to East Siberian Sea 2RV Polarstern on its way to East Siberian Sea 3Genetics reveals big fish that almost got away 2
...bulizers are available in two product models - the... two models is that the 6000AT+ includes a membran... aerosol for improved detection limits and reduced...on limits for a range of elements by 10-40 times. ...
... >95%NEN Radiolabeled Ligands\n\nReceptor-related ...ailability of new radiolabeled ligands selected to...s a wide range of products and services for recept... state-of-the-art radioligands. If you do not find...
AMV RT HC 600 U from Invitrogen
...ding) was developed using a protein engineering ap... DNA binding pocket of wild-type DNase I. These ch...n for DNA. The result is a versatile enzyme that h...intain at least 50% of peak activity in solutions ...
Biology Products: